DJ-1 protects against dopamine toxicity: Implications for parkinson's disease and aging

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 68, Issue 3, 2013, Pages 215-225

  Lev, Nirit ^a   Barhum, Yael ^a   Pilosof, Neri S ^b   Ickowicz, Debby ^a   Cohen, Haim Y ^a   Melamed, Eldad ^a   Offen, Daniel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

DJ 1; Dopamine; Oxidative stress; Parkinson's disease; Reactive oxygen species; VMAT2

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; DJ 1 PROTEIN, MOUSE; DJ-1 PROTEIN, MOUSE; DOPAMINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ONCOPROTEIN; OXIDOPAMINE; REACTIVE OXYGEN METABOLITE; SLC18A2 PROTEIN, MOUSE; SMALL INTERFERING RNA; VESICULAR MONOAMINE TRANSPORTER;

AGING; ANIMAL; ARTICLE; C57BL MOUSE; CELL LINE; DISEASE MODEL; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MOUSE; MOUSE MUTANT; OXIDATIVE STRESS; PARKINSON DISEASE; TRANSGENIC MOUSE; UPREGULATION; WESTERN BLOTTING;

ADRENERGIC AGENTS; AGING; ANIMALS; BLOTTING, WESTERN; CELL LINE; DISEASE MODELS, ANIMAL; DOPAMINE; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; ONCOGENE PROTEINS; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; RNA, SMALL INTERFERING; UP-REGULATION; VESICULAR MONOAMINE TRANSPORT PROTEINS;

MLCS; MLOWN;

EID: 84873665618     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/gls147     Document Type: Article

References (35)

1. Jinsmaa Y, Florang VR, Rees JN, et al. Dopamine-derived biological reactive intermediates and protein modifications: implications for Parkinson's disease. Chem Biol Interact. 2011;192:118-121. doi:10.1016/j.cbi.2011.01.006.
2. Barzilai A, Daily D, Zilkha-Falb R, et al. The molecular mechanisms of dopamine toxicity. Adv Neurol. 2003;91:73-82.
3. Blum D, Torch S, Lambeng N, et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol. 2001;65:135-172. doi:10.1016/S0301- 0082(01)00003-X.
4. Sulzer D. Alpha-synuclein and cytosolic dopamine: stabilizing a bad situation. Nat Med. 2001;7:1280-1282. doi:10.1038/nm1201-1280.
5. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Ann Neurol. 1998;44:S72-S84.
6. Offen D, Ziv I, Sternin H, Melamed E, Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp Neurol. 1996;141:32-39. doi:10.1006/exnr.1996.0136.
7. Lev N, Ickowicz D, Barhum Y, Lev S, Melamed E, Offen D. DJ-1 protects against dopamine toxicity. J Neural Transm. 2009;116:151-160. doi:10.1007/s00702-008-0134-4.
8. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003;302:819-822. doi:10.1126/science.1087753.
9. Sulzer D, Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res. 2000;3:181-195. doi:10.1007/BF03033289.
10. Miyazaki I, Asanuma M, Kikkawa Y, et al. Astrocyte-derived metallothionein protects dopaminergic neurons from dopamine quinone toxicity. Glia. 2011;59:435-451. doi:10.1002/glia.21112.
11. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256-259. doi:10.1126/science.1077209.
12. Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ, Wood NW. The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol. 2003;54:283-286. doi:10.1002/ana.10675.
13. Canet-Aviles RM, Wilson MA, Miller DW, et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA. 2004;101:9103-9108. doi:10.1073/pnas.0402959101.
14. Waak J, Weber SS, Görner K, et al. Oxidizable residues mediating protein stability and cytoprotective interaction of DJ-1 with apoptosis signal-regulating kinase1. J Biol Chem. 2009;284:14245-14257. doi:10.1074/jbc.M806902200.
15. Choi J, Sullards MC, Olzmann JA, et al. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem. 2006;281:10816-10824. doi:10.1074/jbc.M509079200.
16. Kumaran R, Vandrovcova J, Luk C, et al. Differential DJ-1 gene expression in Parkinson's disease. Neurobiol Dis. 2009;36:393-400. doi:10.1016/j.nbd.2009. 08.011.
17. Waragai M, Nakai M, Wei J, et al. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci Lett. 2007;425:18-22. doi:10.1016/j.neulet.2007.08.010.
18. Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010;133:713-726. doi:10.1093/brain/awq008.
19. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011;69:570-580. doi:10.1002/ana.22311.
20. Akazawa YO, Saito Y, Hamakubo T, et al. Elevation of oxidized DJ-1 in the brain and erythrocytes of Parkinson disease model animals. Neurosci Lett. 2010;483:201-205. doi:10.1016/j. neulet.2010.08.007.
21. Lev N, Ickowicz D, Melamed E, Offen D. Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection. Neurotoxicology. 2008;29:397-405. doi:10.1016/j. neuro.2008.01.007.
22. Lee WY, Lee EA, Jeon MY, Kang HY, Park YG. Vesicular monoamine transporter-2 and aromatic l-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent l-3,4-dihydroxyphenylalanine administration. Exp Neurol. 2006;197:215-224. doi:10.1016/j. expneurol.2005.09.012.
23. Guillot TS, Miller GW. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol Neurobiol. 2009;39:149-170. doi:10.1007/s12035-009-8059-y.
24. Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, Brundin P. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem. 2002;277: 38884-38894. doi:10.1074/jbc.M205518200.
25. Olzmann JA, Bordelon JR, Muly EC, et al. Selective enrichment of DJ-1 protein in primate striatal neuronal processes: implications for Parkinson's disease. J Comp Neurol. 2007;500:585-599. doi:10.1002/cne.21191.
26. Xu J, Zhong N, Wang H, et al. The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum Mol Genet. 2005;14:1231-1241. doi:10.1093/hmg/ddi134.
27. Ishikawa S, Taira T, Takahashi-Niki K, Niki T, Ariga H, Iguchi-Ariga SM. Human DJ-1-specific transcriptional activation of tyrosine hydroxylase gene. J Biol Chem. 2010;285:39718-39731. doi:10.1074/jbc.M110.137034.
28. Takahashi N, Miner LL, Sora I, et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA. 1997;94:9938-9994. doi:10.1073/pnas.94.18.9938.
29. Uhl GR, Li S, Takahashi N, et al. The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins. FASEB J. 2000;14: 2459-2465. doi:10.1096/fj.00-0205rev.
30. German DC, Liang CL, Manaye KF, Lane K, Sonsalla PK. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons. Neuroscience. 2000;101:1063-1069. doi:10.1016/S0306-4522(00)00385-7.
31. Glatt CE, Wahner AD, White DJ, Ruiz-Linares A, Ritz B. Gainof-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet. 2006;15:299-305. doi:10.1093/hmg/ ddi445.
32. Kim RH, Smith PD, Aleyasin H, et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci USA. 2005;102: 5215-5220. doi:10.1073/pnas. 0501282102.
33. Paterna JC, Leng A, Weber E, Feldon J, Büeler H. DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice. Mol Ther. 2007;15:698-704. doi:10.1038/sj.mt.6300067.
34. Aleyasin H, Rousseaux MW, Marcogliese PC, et al. DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway. Proc Natl Acad Sci USA. 2010;107:3186-3191. doi:10.1073/pnas.0914876107.
35. Goldstein DS, Holmes C, Kopin IJ, Sharabi Y. Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases. J Clin Invest. 2011;121:3320-3330. doi:10.1172/JCI45803.